Story perspectives

Bristol-Myers Squibb Beats EPS Estimates, Raises Revenue Outlook

4/25/2025

50 4

Summary

Story summary

Bristol-Myers Squibb (BMY) reported Q1 2025 adjusted EPS of $1.80, surpassing estimates of $1.51, with total revenues at $11.2 billion, a 6% decline year-over-year.
The company raised its 2025 revenue guidance to $45.8-$46.8 billion, fueled by a 16% growth in its Growth Portfolio, totaling $5.6 billion.
Despite challenges with its schizophrenia drug Cobenfy, generating $27 million in sales, BMY remains optimistic about its future.
The Legacy Portfolio faced a 20% revenue decline due to generics, impacting drugs like Revlimid and Pomalyst.

History

Historical Context

Bristol-Myers Squibb's recent revenue decline mirrors historical challenges faced by pharmaceutical giants amid patent expirations and generic competition. Similar to the 2009 spin-off of Mead Johnson, the company must adapt its portfolio strategy to maintain growth, highlighting the cyclical nature of the pharmaceutical industry.

1 of 2

Story summary

Bristol-Myers Squibb (BMY) reported Q1 2025 adjusted EPS of $1.80, surpassing estimates of $1.51, with total revenues at $11.2 billion, a 6% decline year-over-year.
The company raised its 2025 revenue guidance to $45.8-$46.8 billion, fueled by a 16% growth in its Growth Portfolio, totaling $5.6 billion.
Despite challenges with its schizophrenia drug Cobenfy, generating $27 million in sales, BMY remains optimistic about its future.
The Legacy Portfolio faced a 20% revenue decline due to generics, impacting drugs like Revlimid and Pomalyst.

1 / 2